Jordan D Dimitrov

List of Publications by Year
in descending order

108	3,119	147566	189595
papers	citations	31 h-index	50 g-index

115	115	115	3696
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Microbial symphony orchestrated by mucosal IgA. Cellular and Molecular Immunology, 2022, , .	4.8	0
2	Functional Changes of Therapeutic Antibodies upon Exposure to Pro-Oxidative Agents. Antibodies, 2022, 11, 11.	1.2	7
3	Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. Journal of Experimental Medicine, 2022, 219, .	4.2	14
4	Induced antigen-binding polyreactivity in human serum IgA. Immunobiology, 2022, 227, 152213.	0.8	3
5	Potent human broadly SARS-CoV-2â€“neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. Journal of Experimental Medicine, 2022, 219, .	4.2	34
6	Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. Haematologica, 2021, 106, 626-629.	1.7	44
7	The receptor for advanced glycation end products is a sensor for cellâ€free heme. FEBS Journal, 2021, 288, 3448-3464.	2.2	16
8	Noncanonical antibody strategy for broad and potent neutralization of influenza virus. Cellular and Molecular Immunology, 2021, 18, 1615-1617.	4.8	0
9	Evaluation of Binding Kinetics and Thermodynamics of Antibodyâ€“Antigen Interactions and Interactions Involving Complement Proteins. Methods in Molecular Biology, 2021, 2227, 237-247.	0.4	1
10	Methods for Assessment of Interactions of Proteins with Heme: Application for Complement Proteins and Immunoglobulins. Methods in Molecular Biology, 2021, 2227, 227-236.	0.4	2
11	Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities. Communications Biology, 2021, 4, 391.	2.0	9
12	Heme: driver of erythrocyte elimination. Blood, 2021, 138, 1092-1094.	0.6	3
13	How can polyreactive antibodies conquer rapidly evolving viruses?. Trends in Immunology, 2021, 42, 654-657.	2.9	7
14	Interaction with 2,4-dinitrophenol correlates with polyreactivity, self-binding, and stability of clinical-stage therapeutic antibodies. Molecular Immunology, 2021, 140, 233-239.	1.0	2
15	Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis. Clinical Reviews in Allergy and Immunology, 2020, 58, 213-228.	2.9	60
16	Anti-IgE IgG autoantibodies isolated from therapeutic normal IgG intravenous immunoglobulin induce basophil activation. Cellular and Molecular Immunology, 2020, 17, 426-429.	4.8	8
17	V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor. Journal of Immunology, 2020, 205, 2850-2860.	0.4	7
18	Method for identification of heme-binding proteins and quantification of their interactions. Analytical Biochemistry, 2020, 607, 113865.	1.1	5

#	Article	IF	Citations
19	Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. Journal of Experimental Medicine, 2020, 217, .	4.2	34
20	Harnessing the Therapeutic Potential of â€˜Rogueâ€™ Antibodies. Trends in Pharmacological Sciences, 2020, 41, 409-417.	4.0	9
21	Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. Frontiers in Immunology, 2020, 11, 810.	2.2	10
22	Stimulation with FITC-labeled antigens confers B cells with regulatory properties. Cellular Immunology, 2020, 355, 104151.	1.4	3
23	Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils. Frontiers in Immunology, 2020, 11, 973.	2.2	4
24	Noncanonical Functions of Antibodies. Trends in Immunology, 2020, 41, 379-393.	2.9	17
25	Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies. Molecular Immunology, 2019, 112, 338-346.	1.0	32
26	Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. Journal of Allergy and Clinical Immunology, 2019, 144, 524-535.e8.	1.5	36
27	Use of cysteine as a spectroscopic probe for determination of heme-scavenging capacity of serum proteins and whole human serum. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 311-319.	1.4	13
28	Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme. Molecular Immunology, 2019, 111, 205-208.	1.0	8
29	P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6280-6285.	3.3	90
30	HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells. Cell Reports, 2019, 27, 572-585.e7.	2.9	21
31	Aromatic Guanylhydrazones for the Control of Heme-Induced Antibody Polyreactivity. ACS Omega, 2019, 4, 20450-20458.	1.6	1
32	Breaking the law: unconventional strategies for antibody diversification. Nature Reviews Immunology, 2019, 19, 355-368.	10.6	63
33	Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. Cellular Immunology, 2018, 325, 64-68.	1.4	4
34	Potential Predictive Role of Lipid Peroxidation Markers for Type 2 Diabetes in the Adult Tunisian Population. Canadian Journal of Diabetes, 2018, 42, 263-271.	0.4	12
35	Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. Frontiers in Immunology, 2018, 9, 3008.	2.2	36
36	Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. Cell Reports, 2018, 23, 2568-2581.	2.9	46

#	Article	IF	Citations
37	Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis. Frontiers in Immunology, 2018, 9, 179.	2.2	41
38	Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight, 2018, 3, .	2.3	135
39	Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival. Inflammation, 2017, 40, 117-122.	1.7	9
40	Atypical hemolytic uremic syndrome â€“ Why the kidney?. Molecular Immunology, 2017, 89, 172-173.	1.0	0
41	Impact of Antigen Density on the Binding Mechanism of IgG Antibodies. Scientific Reports, 2017, 7, 3767.	1.6	40
42	Methods for Posttranslational Induction of Polyreactivity of Antibodies. Methods in Molecular Biology, 2017, 1643, 135-145.	0.4	9
43	Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin. Scientific Reports, 2016, 6, 19592.	1.6	19
44	Relationship between natural and heme-mediated antibody polyreactivity. Biochemical and Biophysical Research Communications, 2016, 472, 281-286.	1.0	6
45	Heme: Modulator of Plasma Systems in Hemolytic Diseases. Trends in Molecular Medicine, 2016, 22, 200-213.	3.5	126
46	Neutralization of Japanese Encephalitis Virus by heme-induced broadly reactive human monoclonal antibody. Scientific Reports, 2015, 5, 16248.	1.6	19
47	Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. Molecular Medicine, 2015, 21, 1002-1010.	1.9	24
48	Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes. Diabetes, 2015, 64, 3532-3542.	0.3	24
49	Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. Journal of Biological Chemistry, 2015, 290, 25343-25355.	1.6	44
50	Prevalence and Gene Characteristics of Antibodies with Cofactor-induced HIV-1 Specificity. Journal of Biological Chemistry, 2015, 290, 5203-5213.	1.6	28
51	Mechanism and Functional Implications of the Heme-Induced Binding Promiscuity of IgE. Biochemistry, 2015, 54, 2061-2072.	1.2	13
52	Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Science Translational Medicine, 2015, 7, 275ra21.	5.8	43
53	Natural and Induced Antibody Polyreactivity. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 1230-1241.	0.9	5
54	Molecular basis for bacterial peptidoglycan recognition by LysM domains. Nature Communications, 2014, 5, 4269.	5.8	167

#	Article	IF	Citations
55	Serum or breast milk immunoglobulins mask the selfâ€reactivity of human natural IgG antibodies. Apmis, 2014, 122, 329-340.	0.9	2
56	Thermodynamic stability contributes to immunoglobulin specificity. Trends in Biochemical Sciences, 2014, 39, 221-226.	3.7	12
57	Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. Molecular Immunology, 2014, 60, 54-61.	1.0	9
58	A Cryptic Polyreactive Antibody Recognizes Distinct Clades of HIV-1 Glycoprotein 120 by an Identical Binding Mechanism. Journal of Biological Chemistry, 2014, 289, 17767-17779.	1.6	19
59	Predictive immunogenicity of Refacto^{Â®}<scp>AF</scp>. Haemophilia, 2014, 20, 486-492.	1.0	11
60	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood, 2014, 123, 121-125.	0.6	63
61	Antibody Polyreactivity in Health and Disease: Statu Variabilis. Journal of Immunology, 2013, 191, 993-999.	0.4	100
62	Antibody-mediated catalysis: Induction and therapeutic relevance. Autoimmunity Reviews, 2013, 12, 648-652.	2.5	24
63	Gain of function of immunoglobulins after partial unfolding or cofactor binding. Molecular Immunology, 2013, 55, 195-196.	1.0	2
64	Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination. Journal of Immunology, 2013, 191, 623-631.	0.4	21
65	Implementation and evaluation of classroom simulation for trainee teacher using second life environments. , 2013, , .		1
66	Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood, 2013, 122, 282-292.	0.6	207
67	Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica, 2013, 98, 1650-1655.	1.7	29
68	Thermodynamic Analysis of the Interaction of Factor VIII with von Willebrand Factor. Biochemistry, 2012, 51, 4108-4116.	1.2	17
69	Comment on Enhancement of the Catalytic Activity of a 27 kDa Subtilisin-like Enzyme from Bacillus amyloliquefaciens CH51 by in Vitro Mutagenesis. Journal of Agricultural and Food Chemistry, 2012, 60, 4170-4172.	2.4	2
70	Antibody Polyspecificity. Advances in Experimental Medicine and Biology, 2012, 750, 213-226.	0.8	28
71	Heme binds to factor VIII and inhibits its interaction with activated factor IX. Journal of Thrombosis and Haemostasis, 2012, 10, 1062-1071.	1.9	20
72	Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter. Blood, 2012, 120, 38-38.	0.6	0

#	Article	IF	Citations
73	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. Journal of Autoimmunity, 2011, 36, 9-15.	3.0	67
74	Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood, 2011, 117, 2257-2264.	0.6	38
75	Bortezomib delays the onset of factorÂVIII inhibitors in experimental hemophiliaÂA, but fails to eliminate established antiâ€factorÂVIII IgGâ€producing cells. Journal of Thrombosis and Haemostasis, 2011, 9, 719-728.	1.9	12
76	Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. Clinical Immunology, 2011, 138, 162-171.	1.4	30
77	Important parameters for evaluation of antibody avidity by immunosorbent assay. Analytical Biochemistry, 2011, 418, 149-151.	1.1	46
78	Heme Interacts with C1q and Inhibits the Classical Complement Pathway. Journal of Biological Chemistry, 2011, 286, 16459-16469.	1.6	56
79	Thermodynamic Analysis of Hepatitis C Virus Vitality in Syringes. Journal of Infectious Diseases, 2011, 203, 1696-1697.	1.9	2
80	â€œRational Vaccine Designâ€•for HIV Should Take into Account the Adaptive Potential of Polyreactive Antibodies. PLoS Pathogens, 2011, 7, e1002095.	2.1	12
81	Induction of heme oxygenase-1 in factor VIIIâ€“deficient mice reduces the immune response to therapeutic factor VIII. Blood, 2010, 115, 2682-2685.	0.6	28
82	A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. Journal of Thrombosis and Haemostasis, 2010, 8, 1524-1531.	1.9	13
83	Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. FEBS Journal, 2010, 277, 3039-3050.	2.2	53
84	Metrics: journal's impact factor skewed by a single paper. Nature, 2010, 466, 179-179.	13.7	33
85	TCR Stimulation Drives Cleavage and Shedding of the ITIM Receptor CD31. Journal of Immunology, 2010, 184, 5485-5492.	0.4	58
86	Heterogeneous antigen recognition behavior of induced polyspecific antibodies. Biochemical and Biophysical Research Communications, 2010, 398, 266-271.	1.0	27
87	Inhibitors of Factor VIII in Hemophilia. New England Journal of Medicine, 2009, 361, 308-310.	13.9	3
88	Factor VIIIâ€hydrolyzing IgG in acquired and congenital hemophilia. FEBS Letters, 2009, 583, 2565-2572.	1.3	18
89	A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A. Clinical Reviews in Allergy and Immunology, 2009, 37, 105-113.	2.9	24
90	Identification of target antigens of selfâ€reactive IgG in intravenous immunoglobulin preparations. Proteomics, 2009, 9, 2253-2262.	1.3	27

#	Article	IF	Citations
91	Cofactor-mediated protein promiscuity. Nature Biotechnology, 2009, 27, 892-892.	9.4	16
92	Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Molecular Immunology, 2009, 47, 290-297.	1.0	6
93	Protein destabilizing agents induce polyreactivity and enhanced immunomodulatory activity in IVIg preparations. Autoimmunity, 2009, 42, 365-367.	1.2	17
94	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood, 2009, 114, 2837-2845.	0.6	140
95	Inflammation-induced enhancement of IgG immunoreactivity. Inflammation Research, 2008, 57, 1-3.	1.6	52
96	Insight into the mechanism of the acquired antibody auto-reactivity. Autoimmunity Reviews, 2008, 7, 410-414.	2.5	15
97	Functional variability of antibodies upon oxidative processes. Autoimmunity Reviews, 2008, 7, 574-578.	2.5	18
98	Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins. Journal of Immunology, 2008, 181, 1609-1615.	0.4	18
99	Factor VIII Hydrolysis Mediated by Anti-Factor VIII Autoantibodies in Acquired Hemophilia. Journal of Immunology, 2008, 180, 7714-7720.	0.4	45
100	Hydrolysis of Coagulation Factors by Circulating IgG Is Associated with a Reduced Risk for Chronic Allograft Nephropathy in Renal Transplanted Patients. Journal of Immunology, 2008, 180, 8455-8460.	0.4	22
101	Antibodies Use Heme as a Cofactor to Extend Their Pathogen Elimination Activity and to Acquire New Effector Functions. Journal of Biological Chemistry, 2007, 282, 26696-26706.	1.6	81
102	Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases?. Nephrology Dialysis Transplantation, 2007, 22, 1301-1304.	0.4	8
103	Transition towards antigen-binding promiscuity of a monospecific antibody. Molecular Immunology, 2007, 44, 1854-1863.	1.0	33
104	Iron Ions and Haeme Modulate the Binding Properties of Complement Subcomponent C1q and of Immunoglobulins. Scandinavian Journal of Immunology, 2007, 65, 230-239.	1.3	32
105	Ferrous Ions and Reactive Oxygen Species Increase Antigen-binding and Anti-inflammatory Activities of Immunoglobulin G. Journal of Biological Chemistry, 2006, 281, 439-446.	1.6	72
106	Molecular composition of diphtheria toxoid produced using semi-synthetic and meat extract-based broths. World Journal of Microbiology and Biotechnology, 2004, 20, 211-217.	1.7	2
107	Optimization of casein-based semisynthetic medium for growing of toxigenic Corinebacterium diphtheriae in a fermenter. Canadian Journal of Microbiology, 2004, 50, 821-826.	0.8	7
108	Anaerobic Bacteriology in 75 Cases of Thoracic Empyema in Sofia, Bulgaria. Anaerobe, 2000, 6, 81-85.	1.0	2